We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
The current MSCL market cap is 63.16M. The company's latest EPS is CAD -0.1409 and P/E is -2.84.
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| CAD ($) | CAD ($) | CAD ($) | CAD ($) | CAD ($) | |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -1.07M | -1.04M | -3.25M | -9.72M | -13.03M |
| Net Income | -1.94M | -1.49M | -15.51M | -11.32M | -15.89M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| CAD ($) | CAD ($) | CAD ($) | CAD ($) | CAD ($) | |
| Total Assets | 1.47M | 546k | 12.59M | 6.2M | 44.3M |
| Total Liabilities | 807k | 1.3M | 2.1M | 2.83M | 3.62M |
| Total Equity | 661k | -750k | 10.48M | 3.37M | 40.67M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| CAD ($) | CAD ($) | CAD ($) | CAD ($) | CAD ($) | |
| Operating | -2.24M | -907k | -5.03M | -5.64M | -14.5M |
| Investing | -6k | N/A | 1.74M | -3k | -17.54M |
| Financing | 3.22M | N/A | 7.45M | 2.78M | 51.03M |
| Market Cap | 63.16M |
| Price to Earnings Ratio | -2.84 |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 2.04 |
| Price to Book Ratio | 1.11 |
| Dividend Yield | - |
| Shares Outstanding | 112.79M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | -17.65% |
| 52 Week High | 0.68 |
| 52 Week Low | 0.29 |
| Spread (Intraday) | 0.01 (1.75%) |
| Company Name | Satellos Bioscience Inc |
| Address |
79 wellington street west, 33rd floor toronto, ontario M5K 1N2 |
| Website | https://www.satellos.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
